Ani Pharmaceuticals Inc
ANIP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001023024
In the last 90 days, Ani Pharmaceuticals Inc insiders filed 0 open-market purchases and 11 sales; 321 institutions reported holding it in 13F filings for Q2 2026, worth $2.27B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $2.18M in total
- 11
- 13F holdersQ2 2026, +28 vs. previous quarter
- 321
- 13F valueReported value at the end of Q2 2026
- $2.27B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ANIP, Q2 2026
No superinvestor reported holding ANIP at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Ani Pharmaceuticals Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 (view filing)4:20 PM ET | Sep 15 | 1 day | Lalwani NikhilPRESIDENT & CEO | SSale | −5.40K | $71.00 | −$383.4K | −1.6%339.1K after | 10b5-1 |
| Sep 14, 2026 (view filing)8:57 PM ET | Sep 11 | 3 days | Thoma JeanneDirector | SSale | −1.00K | $71.53 | −$71.5K | −3.6%26.8K after | 10b5-1 |
| Sep 14, 2026 (view filing)8:56 PM ET | Sep 14 | Same day | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | SSale | −500 | $70.79 | −$35.4K | −0.7%73.9K after | 10b5-1 |
| Sep 1, 2026 (view filing)6:18 PM ET | Aug 31 | 1 day | Carey Stephen P.SVP & CFO | SSale | −2.85K | $72.80 | −$207.5K | −1.6%171.8K after | 10b5-1 |
| Aug 26, 2026 (view filing)6:15 PM ET | Aug 25 | 1 day | Lalwani NikhilPRESIDENT & CEO | SSale | −5.40K | $74.30 | −$401.2K | −1.5%344.5K after | 10b5-1 |
| Aug 13, 2026 (view filing)4:32 PM ET | Aug 13 | Same day | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | SSale | −500 | $75.48 | −$37.7K | −0.7%74.4K after | 10b5-1 |
| Aug 11, 2026 (view filing)8:57 PM ET | Aug 10 | 1 day | Gutwerg OriSVP, GENERICS | SSale | −3.16K | $77.00 | −$243.5K | −4.0%75.5K after | |
| Jul 30, 2026 (view filing)4:02 PM ET | Jul 29 | 1 day | Carey Stephen P.SVP & CFO | SSale | −2.85K | $81.36 | −$231.9K | −1.6%174.7K after | 10b5-1 |
| Jul 14, 2026 (view filing)4:02 PM ET | Jul 13 | 1 day | Cook MeredithSR. VP, GENERAL COUNSEL & SEC. | SSale | −500 | $81.84 | −$40.9K | −0.6%77.4K after | 10b5-1 |
| Jul 6, 2026 (view filing)9:40 PM ET | Jul 2 | 4 days | Carey Stephen P.SVP & CFO | SSale | −3.31K | $86.00 | −$284.9K | −1.8%177.5K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Ani Pharmaceuticals Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 2,958,646 | $264.4M | 0.00% | +211,154+7.7% | Added |
| Soleus Capital Management, L.P. | 867,760 | $71.8M | 2.48% | +47,517+5.8% | Added |
| Vanguard Capital Management LLC | 838,224 | $69.4M | 0.00% | +15,160+1.8% | Added |
| State Street Corp | 831,647 | $68.9M | 0.00% | +60,060+7.8% | Added |
| Point72 Asset Management, L.P. | – | $62.0M | 0.09% | – | – |
| Tang Capital Management LLC | 707,500 | $58.6M | 2.66% | 00.0% | Unchanged |
| Citadel Advisors LLC | 96,082 | $53.4M | 0.03% | −19,000−16.5% | Reduced |
| Dimensional Fund Advisors LP | 623,463 | $51.6M | 0.01% | +92,273+17.4% | Added |
| American Century Companies Inc | 574,474 | $47.6M | 0.02% | +382,898+199.9% | Added |
| Arrowstreet Capital, Limited Partnership | 562,016 | $46.5M | 0.02% | −2,344−0.4% | Reduced |